Exact Sciences Corporation (NASDAQ:EXAS) – Research analysts at William Blair boosted their FY2017 earnings per share estimates for Exact Sciences Corporation in a research note issued to investors on Monday. William Blair analyst B. Weinstein now expects that the medical research company will post earnings per share of ($1.12) for the year, up from their previous estimate of ($1.20). William Blair also issued estimates for Exact Sciences Corporation’s Q4 2017 earnings at ($0.31) EPS, Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.18) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.03) EPS and FY2018 earnings at ($0.54) EPS.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The business had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The company’s quarterly revenue was up 158.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.36) EPS.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/02/fy2017-eps-estimates-for-exact-sciences-corporation-boosted-by-analyst-exas.html.

Several other equities analysts have also commented on EXAS. Vetr lowered Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 price target on the stock. in a research note on Thursday, July 6th. Craig Hallum lifted their target price on Exact Sciences Corporation from $35.00 to $41.00 in a research note on Friday, July 7th. Benchmark Co. set a $50.00 price target on Exact Sciences Corporation and gave the stock a “buy” rating in a research note on Friday, July 7th. BTIG Research restated a “buy” rating and set a $45.00 price target (up previously from $35.00) on shares of Exact Sciences Corporation in a research note on Monday, July 17th. Finally, Canaccord Genuity restated a “buy” rating and set a $42.00 price target (up previously from $38.00) on shares of Exact Sciences Corporation in a research note on Thursday, July 20th. Six equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $49.71.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Exact Sciences Corporation by 8.0% during the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock worth $334,589,000 after purchasing an additional 700,051 shares in the last quarter. BlackRock Inc. increased its position in shares of Exact Sciences Corporation by 1.2% during the second quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock worth $243,518,000 after purchasing an additional 80,589 shares in the last quarter. Fred Alger Management Inc. purchased a new stake in shares of Exact Sciences Corporation during the second quarter worth approximately $84,177,000. Lord Abbett & CO. LLC increased its position in shares of Exact Sciences Corporation by 59.1% during the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock worth $83,357,000 after purchasing an additional 875,527 shares in the last quarter. Finally, FMR LLC increased its position in shares of Exact Sciences Corporation by 32.7% during the second quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock worth $81,997,000 after purchasing an additional 571,796 shares in the last quarter. Hedge funds and other institutional investors own 85.12% of the company’s stock.

In related news, SVP D Scott Coward sold 29,115 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares in the company, valued at $3,064,975.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Graham Peter Lidgard sold 81,025 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now owns 366,519 shares of the company’s stock, valued at $17,285,036.04. The disclosure for this sale can be found here. Insiders sold 231,598 shares of company stock valued at $10,182,030 over the last 90 days. Company insiders own 4.00% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.